AI is transforming life sciences but raising risk concerns, new benchmark report finds

Managing IP is part of Legal Benchmarking Limited, 1-2 Paris Gardens, London, SE1 8ND

Copyright © Legal Benchmarking Limited and its affiliated companies 2025

Accessibility | Terms of Use | Privacy Policy | Modern Slavery Statement

AI is transforming life sciences but raising risk concerns, new benchmark report finds

Sponsored by

Arnold and Porter logo.png
Arnold & Porter image.jpg

A new survey by Arnold & Porter reveals that AI adoption in life sciences is accelerating, driving innovation in drug discovery, manufacturing, and sales. The report highlights the evolution in the adoption of the technology that needs to be accompanied by good risk assessment and compliance practices

A new report commissioned by Arnold & Porter, based on a survey of 100 senior executives and department heads from biopharmaceutical, digital health, diagnostics, and medical device companies, shows that AI adoption is accelerating across the industry as companies implement it to accelerate product discovery and development, optimise manufacturing and the supply chain, improve marketing and sales strategies, and more.

However, as with any disruptive innovation, risks need to be managed. The report also highlights looming governance and compliance needs as companies seek to mitigate the risks associated with AI technologies, particularly in areas such as data privacy, cybersecurity, and intellectual property.

The Arnold & Porter report found that AI use is still in its early stages for many in the life sciences industry, with around 75% of respondents beginning implementation less than two years ago. Despite this, 86% of companies currently integrating AI plan to fully deploy these tools within the next two years, reflecting a significant acceleration in AI adoption.

R&D leading AI use, with commercial functions close behind

R&D emerged as the leading area of AI implementation, with 79% of respondents actively using, or planning to use, AI to drive faster, more efficient drug discovery and clinical trials. AI is also making inroads into manufacturing (62%), marketing (45%), and regulatory functions (42%) as companies seek to harness the power of AI across the entire product life cycle.

Governance amid rapid AI adoption

Despite AI’s rapid pace, AI governance is an ongoing challenge for many life sciences companies. According to the survey, only 55% of companies currently using AI have implemented formal AI policies or standard operating procedures. Even fewer – just 51% of companies – have completed regular AI audits or assembled cross-functional teams to oversee safe and compliant AI use. This data suggests that companies will need to prioritise risk management and compliance more to realise AI's full potential without exposing themselves to unnecessary vulnerabilities.

AI's impact on product discovery and sales

The survey found that AI already delivers tangible benefits in the product discovery and commercialisation phases. Approximately half of respondents have explored leveraging AI to optimise product discovery and design, citing anticipated faster time to market and improved efficiency as key drivers. Additionally, 85% of respondents reported that AI-driven initiatives to boost commercial effectiveness have been highly productive.

IP concerns loom as AI expands

The survey also uncovered rising concerns over AI-related intellectual property issues. Nearly three-quarters (74%) of respondents expressed significant concern about the potential for AI to introduce new intellectual property challenges within the next year. As AI-driven innovations continue to reshape the industry, life sciences companies are increasingly vigilant about protecting their breakthroughs.

Looking ahead: AI's growing role in life sciences

As AI becomes more embedded in life sciences operations, its role in patient care and diagnostics is expected to grow. The survey suggests that AI-enabled diagnostic tools, clinical trials, and AI-assisted treatment plans will soon become standard across the healthcare industry. However, given that regulators are already signalling heightened scrutiny of AI use from a compliance perspective, companies must address governance gaps to ensure safe, effective, and compliant use as they progress with AI integration.

Arnold & Porter's full report, The Convergence of Life Sciences and Artificial Intelligence: Seizing Opportunities While Managing Risk, can be found here. It also features in-depth analyses of the survey results and additional resources on AI issues in product design and discovery, intellectual property, medical device regulations, clinical development, privacy and cybersecurity, manufacturing and supply chain, commercialisation, payments, governance and compliance, implementation, global considerations, and more.

About Arnold & Porter

Arnold & Porter combines sophisticated regulatory, litigation, and transactional capabilities to resolve clients’ most complex issues. With over 1,000 lawyers practising in 15 offices worldwide, the firm offers deep industry experience and an integrated approach that spans more than 40 practice areas. Through multidisciplinary collaboration and focused industry experience, the firm provides innovative and effective solutions to mitigate risks, address challenges, and achieve successful outcomes.

more from across site and SHARED ros bottom lb

More from across our site

Attorneys explain why there are early signs that the US Supreme Court could rule in favour of ISP Cox in a copyright dispute
A swathe of UPC-related hires suggests firms are taking the forum seriously, as questions over the transitional stage begin
A win for Nintendo in China and King & Spalding hiring a prominent patent litigator were also among the top talking points
Rebecca Newman at Addleshaw Goddard, who live-reported on the seminal dispute, unpicks the trials and tribulations of the case and considers its impact
Attorneys predict how Lululemon’s trade dress and design patent suit against Costco could play out
Lawyers at Linklaters analyse some of the key UPC trends so far, and look ahead to life beyond the transition period
David Rodrigues, who previously worked at an IP boutique, said he may become more involved in transactional work at his new firm
Indian smartphone maker Lava must pay $2.3 million as a security deposit for past sales, as its dispute with Dolby over audio coding SEPs plays out
Powell Gilbert’s opening in Düsseldorf, complete with a new partner hire, continues this summer’s trend of UPC-related lateral movement
IP leaders at Brandsmiths and Bird & Bird, who were on opposing sides at the UK Supreme Court in Iconix v Dream Pairs, unpick the landmark case and its ramifications
Gift this article